{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:29:29Z","timestamp":1788294569622,"version":"build-2803163510"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H00968"],"award-info":[{"award-number":["19H00968"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23H00357"],"award-info":[{"award-number":["23H00357"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Immunology and Immunopathology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.vetimm.2025.111019","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:44:20Z","timestamp":1761493460000},"page":"111019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Sorafenib inhibits myeloid-derived suppressor cell infiltration in canine transitional cell carcinoma"],"prefix":"10.1016","volume":"290","author":[{"given":"Shohei","family":"Yokota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Motegi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reo","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Momoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1413-1258","authenticated-orcid":false,"given":"Shingo","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vetimm.2025.111019_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.tvjl.2015.01.017","article-title":"Management of transitional cell carcinoma of the urinary bladder in dogs: a review","volume":"205","author":"Fulkerson","year":"2015","journal-title":"Vet. J."},{"issue":"1","key":"10.1016\/j.vetimm.2025.111019_bib2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/ilar\/ilu018","article-title":"Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development","volume":"55","author":"Knapp","year":"2014","journal-title":"ILAR J."},{"key":"10.1016\/j.vetimm.2025.111019_bib3","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/pros.20590","article-title":"A population study of neutering status as a risk factor for canine prostate cancer","volume":"67","author":"Bryan","year":"2007","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.vetimm.2025.111019_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3233\/BLC-150044","article-title":"A nonselective cyclooxygenase inhibitor enhances the activity of vinblastine in a naturally-occurring canine model of invasive urothelial carcinoma","volume":"2","author":"Knapp","year":"2016","journal-title":"Bladder Cancer"},{"issue":"1","key":"10.1016\/j.vetimm.2025.111019_bib5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/jvim.12013","article-title":"Randomized trial of cisplatin versus firocoxib versus cisplatin\/firocoxib in dogs with transitional cell carcinoma of the urinary bladder","volume":"27","author":"Knapp","year":"2012","journal-title":"J. Vet. Intern. Med."},{"issue":"2","key":"10.1016\/j.vetimm.2025.111019_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4049\/jimmunol.1701019","article-title":"Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment","volume":"200","author":"Ostrand-Rosenberg","year":"2018","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.vetimm.2025.111019_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.vetimm.2025.111019_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119083","article-title":"The role of myeloid-derived suppressor cells in rheumatoid arthritis: an update","volume":"269","author":"Navashenaq","year":"2021","journal-title":"Life Sci."},{"issue":"11","key":"10.1016\/j.vetimm.2025.111019_bib9","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00262-013-1475-x","article-title":"Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients","volume":"62","author":"Jordan","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.vetimm.2025.111019_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40425-014-0031-3","article-title":"Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate gvax and ipilimumab","volume":"2","author":"Santegoets","year":"2014","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.vetimm.2025.111019_bib11","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00262-015-1765-6","article-title":"Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK\/T cell lymphoma: a novel prognostic indicator","volume":"64","author":"Zhang","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"issue":"15","key":"10.1016\/j.vetimm.2025.111019_bib12","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1038\/onc.2016.367","article-title":"CXCL2\/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer","volume":"36","author":"Zhang","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.vetimm.2025.111019_bib13","first-page":"718","article-title":"Prognostic role of immune cells in hepatocellular carcinoma","volume":"19","author":"Sachdeva","year":"2020","journal-title":"EXCLI J."},{"issue":"5","key":"10.1016\/j.vetimm.2025.111019_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.616","article-title":"Elevated circulating myeloid-derived suppressor cells associated with poor prognosis in B-cell non-Hodgkin\u2019s lymphoma patients","volume":"10","author":"Wang","year":"2022","journal-title":"Immun. Inflamm. Dis."},{"issue":"1","key":"10.1016\/j.vetimm.2025.111019_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41391-022-00615-5","article-title":"Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis","volume":"26","author":"Bronte","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.vetimm.2025.111019_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.799455","article-title":"Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade","volume":"12","author":"Genova","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.vetimm.2025.111019_bib17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"5","key":"10.1016\/j.vetimm.2025.111019_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/imcb.12225","article-title":"The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1\/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas","volume":"97","author":"Ren","year":"2019","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.vetimm.2025.111019_bib19","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/jitc-2020-001657","article-title":"Regorafenib enhances antitumor immunity via inhibition of p38 kinase\/ Creb1\/Klf4 axis in tumor-associated macrophages","volume":"9","author":"Ou","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.vetimm.2025.111019_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1158857","article-title":"Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1-3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment","volume":"13","author":"Liao","year":"2023","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.vetimm.2025.111019_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001496","article-title":"SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation","volume":"9","author":"Redin","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.vetimm.2025.111019_bib22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/labinvest.2010.205","article-title":"Kinase inhibitor sorafenib modulates immunosuppressive cell populations in a murine liver cancer model","volume":"91","author":"Cao","year":"2011","journal-title":"Lab Invest"},{"issue":"6","key":"10.1016\/j.vetimm.2025.111019_bib23","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.3892\/or.2015.3893","article-title":"Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells","volume":"33","author":"Motoshima","year":"2015","journal-title":"Oncol. Rep."},{"issue":"11","key":"10.1016\/j.vetimm.2025.111019_bib24","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1158\/1078-0432.CCR-06-2667","article-title":"Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor \u03b2 gatekeeper mutants","volume":"13","author":"Guida","year":"2007","journal-title":"Clin. Cancer Res"},{"issue":"5","key":"10.1016\/j.vetimm.2025.111019_bib25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/aps.2017.5","article-title":"New knowledge of the mechanisms of sorafenib resistance in liver cancer","volume":"38","author":"Zhu","year":"2017","journal-title":"Acta Pharm. Sin."},{"issue":"5","key":"10.1016\/j.vetimm.2025.111019_bib26","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/ijc.28772","article-title":"VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study","volume":"135","author":"Scartozzi","year":"2014","journal-title":"Int J. Cancer"},{"issue":"5","key":"10.1016\/j.vetimm.2025.111019_bib27","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1159\/000491058","article-title":"Melatonin synergizes with sorafenib to suppress pancreatic cancer via melatonin receptor and PDGFR-\u03b2\/STAT3 Pathway","volume":"47","author":"Fang","year":"2018","journal-title":"Cell Physiol. Biochem"},{"issue":"3","key":"10.1016\/j.vetimm.2025.111019_bib28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/cells9030561","article-title":"Myeloid-derived suppressor cells as a therapeutic target for cancer","volume":"9","author":"Law","year":"2020","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.vetimm.2025.111019_bib29","doi-asserted-by":"crossref","first-page":"872","DOI":"10.4161\/cbt.12.10.17672","article-title":"Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC)","volume":"12","author":"Li","year":"2011","journal-title":"Cancer Biol. Ther."},{"issue":"7","key":"10.1016\/j.vetimm.2025.111019_bib30","doi-asserted-by":"crossref","first-page":"40420","DOI":"10.1371\/journal.pone.0040420","article-title":"Met receptor tyrosine kinase signaling induces 105 secretion of the angiogenic chemokine Interleukin-8\/CXCL8 in pancreatic cancer","volume":"7","author":"Hill","year":"2012","journal-title":"PLoS One"},{"issue":"47","key":"10.1016\/j.vetimm.2025.111019_bib31","doi-asserted-by":"crossref","first-page":"77257","DOI":"10.18632\/oncotarget.12629","article-title":"PDGFR-alpha inhibits melanoma growth via CXCL10\/IP-10: a multi- omics approach","volume":"7","author":"D\u2019Arcangelo","year":"2016","journal-title":"Oncotarget"},{"issue":"43","key":"10.1016\/j.vetimm.2025.111019_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1126\/sciimmunol.aav3937","article-title":"Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non\u2013small cell lung cancer","volume":"5","author":"Sugiyama","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.vetimm.2025.111019_bib33","doi-asserted-by":"crossref","first-page":"110716","DOI":"10.1016\/j.vetimm.2024.110716","article-title":"Myeloid derived suppressor cells in peripheral blood can be a prognostic factor in canine transitional cell carcinoma","volume":"269","author":"Yokota","year":"2024","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"1","key":"10.1016\/j.vetimm.2025.111019_bib34","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1111\/vco.12344","article-title":"Expression of receptor tyrosine kinase targets PDGFR-\u03b2, VEGFR2 and KIT in canine transitional cell carcinoma","volume":"16","author":"Walters","year":"2018","journal-title":"Vet. Comp. Oncol."},{"issue":"2","key":"10.1016\/j.vetimm.2025.111019_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/10406387221146247","article-title":"Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-\u03b2, and CDK4 in canine urothelial carcinoma","volume":"35","author":"Setyo","year":"2023","journal-title":"J. Vet. Diagn. Invest"},{"issue":"6","key":"10.1016\/j.vetimm.2025.111019_bib36","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1541-7786.MCR-14-0689","article-title":"Homologous mutation to human BRAF V600E is common in naturally occurring canine bladder cancer-evidence for a relevant model system and urine-based diagnostic test","volume":"13","author":"Decker","year":"2015","journal-title":"Mol. Cancer Res"},{"issue":"6","key":"10.1016\/j.vetimm.2025.111019_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129534","article-title":"BRAF mutations in canine cancers","volume":"10","author":"Mochizuki","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.vetimm.2025.111019_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033274","article-title":"Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer","volume":"7","author":"Goulart","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vetimm.2025.111019_bib39","article-title":"Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy","volume":"216","author":"Huchison","year":"2019","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2025.111019_bib40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.coi.2010.01.021","article-title":"Myeloid-derived suppressor cell heterogeneity and subset definition This review comes from a themed issue on tumour Immunology","volume":"22","author":"Peranzoni","year":"2010","journal-title":"Curr. Opin. Immunol."},{"issue":"13","key":"10.1016\/j.vetimm.2025.111019_bib41","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.3390\/jcm10132872","article-title":"Clinical medicine review MDSC in mice and men: mechanisms of immunosuppression in cancer","volume":"10","author":"Vanhaver","year":"2021","journal-title":"J. Clin. Med"},{"issue":"38","key":"10.1016\/j.vetimm.2025.111019_bib42","first-page":"512","article-title":"Evaluation of proliferative disorders in canine bone marrow by use of flow cytometric scatter plots and monoclonal antibodies","volume":"2001","author":"Weiss","year":"2012","journal-title":"Vet. Pathol."},{"issue":"1-2","key":"10.1016\/j.vetimm.2025.111019_bib43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.vetimm.2007.04.008","article-title":"Toll-like receptor 3 (TLR3): a new marker of canine monocytes-derived dendritic cells (cMo-DC)","volume":"118","author":"Bonnefont-Rebeix","year":"2007","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"1-2","key":"10.1016\/j.vetimm.2025.111019_bib44","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.vetimm.2011.10.018","article-title":"Molecular cloning and characterization of canine fractalkine and its receptor CX3CR1","volume":"145","author":"Maeda","year":"2012","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"1","key":"10.1016\/j.vetimm.2025.111019_bib45","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41598-019-40285-3","article-title":"Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells","volume":"9","author":"Goulart","year":"2019","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.vetimm.2025.111019_bib46","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/jcmm.12585","article-title":"Cardiac regenerative potential of cardiosphere-derived cells from adult dog hearts","volume":"19","author":"Hensley","year":"2015","journal-title":"J. Cell Mol. Med"},{"issue":"1","key":"10.1016\/j.vetimm.2025.111019_bib47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.tvjl.2015.02.009","article-title":"SiRNA knockdown of the DEK nuclear protein mRNA enhances apoptosis and chemosensitivity of canine transitional cell carcinoma cells","volume":"204","author":"Yamazaki","year":"2015","journal-title":"Vet. J."},{"key":"10.1016\/j.vetimm.2025.111019_bib48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.tvjl.2017.02.001","article-title":"Molecular investigation of the direct anti-tumour effects of nonsteroidal anti-inflammatory drugs in a panel of canine cancer cell lines","volume":"221","author":"Yoshitake","year":"2017","journal-title":"Vet. J."},{"issue":"6","key":"10.1016\/j.vetimm.2025.111019_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218382","article-title":"Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells","volume":"14","author":"Eto","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vetimm.2025.111019_bib50","doi-asserted-by":"crossref","first-page":"7826","DOI":"10.1038\/s41598-020-64832-5","article-title":"Aberrant expression of the COX2\/PGE2 axis is induced by activation of the RAF\/MEK\/ERK pathway in BRAFV595E canine urothelial carcinoma","volume":"10","author":"Yoshitake","year":"2020","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.vetimm.2025.111019_bib51","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1245\/s10434-008-9876-3","article-title":"Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma","volume":"15","author":"Hyakudomi","year":"2008","journal-title":"Ann. Surg. Oncol."},{"issue":"11","key":"10.1016\/j.vetimm.2025.111019_bib52","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"issue":"3","key":"10.1016\/j.vetimm.2025.111019_bib53","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.vetimm.2025.111019_bib54","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/sj.bjc.6605366","article-title":"Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors","volume":"101","author":"Kumar","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.vetimm.2025.111019_bib55","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor angiogenesis and vascular normalization: alternative therapeutic targets","volume":"20","author":"Viallard","year":"2017","journal-title":"Angiogenes"},{"key":"10.1016\/j.vetimm.2025.111019_bib56","doi-asserted-by":"crossref","first-page":"8922.","DOI":"10.1126\/scitranslmed.abc8922","article-title":"Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy","volume":"13","author":"Sun","year":"2021","journal-title":"Sci. Transl. Med"},{"issue":"5","key":"10.1016\/j.vetimm.2025.111019_bib57","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1292\/jvms.21-0478","article-title":"Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma","volume":"84","author":"Yokota","year":"2022","journal-title":"J. Vet. Med Sci."},{"issue":"20","key":"10.1016\/j.vetimm.2025.111019_bib58","doi-asserted-by":"crossref","first-page":"7619","DOI":"10.3390\/ijms21207619","article-title":"Cc chemokines in a tumor: a review of pro-cancer and anti-cancer properties of receptors ccr5, ccr6, ccr7, ccr8, ccr9, and ccr10 ligands","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.vetimm.2025.111019_bib59","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1080\/14397595.2016.1213481","article-title":"Fractalkine\/CX3CL1 in rheumatoid arthritis","volume":"27","author":"Nanki","year":"2017","journal-title":"Mod. Rheuma"},{"key":"10.1016\/j.vetimm.2025.111019_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.664202","article-title":"Fractalkine (CX3CL1) and its receptor CX3CR1: a promising therapeutic target in chronic kidney disease?","volume":"12","author":"Cormican","year":"2021","journal-title":"Front Immunol."},{"issue":"41","key":"10.1016\/j.vetimm.2025.111019_bib61","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.2174\/0929867329666220629140540","article-title":"Structure and function of ligand CX3CL1 and its receptor CX3CR1 in cancer","volume":"29","author":"Lu","year":"2022","journal-title":"Curr. Med Chem."},{"issue":"5","key":"10.1016\/j.vetimm.2025.111019_bib62","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/imcb.12225","article-title":"The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1\/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas","volume":"97","author":"Ren","year":"2019","journal-title":"Immunol. Cell Biol."},{"issue":"18","key":"10.1016\/j.vetimm.2025.111019_bib63","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1016\/j.ejca.2010.07.022","article-title":"Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1","volume":"46","author":"Erreni","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.vetimm.2025.111019_bib64","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s11605-012-1921-7","article-title":"High expression of CX3CL1\/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma","volume":"16","author":"Xu","year":"2012","journal-title":"J. Gastrointest. Surg."},{"issue":"1","key":"10.1016\/j.vetimm.2025.111019_bib65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1541-7786.MCR-11-0256","article-title":"Fractalkine receptor CX 3CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells","volume":"10","author":"Kim","year":"2012","journal-title":"Mol. Cancer Res"},{"issue":"14","key":"10.1016\/j.vetimm.2025.111019_bib66","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1158\/0008-5472.CAN-12-3828","article-title":"CX3CL1 promotes breast cancer via transactivation of the EGF pathway","volume":"73","author":"Tard\u00e1guila","year":"2013","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.vetimm.2025.111019_bib67","doi-asserted-by":"crossref","first-page":"7907","DOI":"10.3892\/mmr.2015.4438","article-title":"Upregulation of fractalkine contributes to the proliferative response of prostate cancer cells to hypoxia via promoting the G1\/S phase transition","volume":"2","author":"Tang","year":"2015","journal-title":"Mol. Med Rep."},{"issue":"9","key":"10.1016\/j.vetimm.2025.111019_bib68","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.yexcr.2010.02.018","article-title":"CX3CR1 promotes recruitment of human glioma-infiltrating microglia\/macrophages (GIMs)","volume":"316","author":"Held-Feindt","year":"2010","journal-title":"Exp. Cell Res"},{"issue":"22","key":"10.1016\/j.vetimm.2025.111019_bib69","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1158\/0008-5472.CAN-22-1199","article-title":"Postoperative plasmacytoid dendritic cells secrete IFN\u03b1 to promote recruitment of myeloid-derived suppressor cells and drive hepatocellular carcinoma recurrence","volume":"82","author":"Pang","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.vetimm.2025.111019_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.752860","article-title":"The clinical implications and molecular mechanism of CX3CL1 expression in urothelial bladder cancer","volume":"11","author":"Jiang","year":"2021","journal-title":"Front Oncol."},{"issue":"8","key":"10.1016\/j.vetimm.2025.111019_bib71","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00262-007-0441-x","article-title":"The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients","volume":"57","author":"Osada","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.vetimm.2025.111019_bib72","first-page":"881","article-title":"The contribution of vascular endothelial growth factor to the induction of regulatory T- cells in malignant effusions","volume":"29","author":"Wada","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.vetimm.2025.111019_bib73","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/path.3989","article-title":"Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages","volume":"22781","author":"Linde","year":"2012","journal-title":"J. Pathol."},{"issue":"330","key":"10.1016\/j.vetimm.2025.111019_bib74","article-title":"Immunomodulatory activity of VEGF in cancer","volume":"2017","author":"Lapeyre-Prost","year":"2020","journal-title":"Int Rev. Cell Mol. Biol."},{"issue":"6","key":"10.1016\/j.vetimm.2025.111019_bib75","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.vetimm.2025.111019_bib76","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.vetimm.2025.111019_bib77","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-18-0751","article-title":"CCR4 blockade depletes regulatory T cells and prolongs survival in a canine model of bladder cancer","volume":"7","author":"Maeda","year":"2019","journal-title":"Cancer Immunol. Res"},{"issue":"6","key":"10.1016\/j.vetimm.2025.111019_bib78","first-page":"2381","article-title":"Expression of VEGF and its receptors VEGFR1\/VEGFR2 is associated with invasiveness of bladder cancer","volume":"33","author":"Kopparapu","year":"2013","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.vetimm.2025.111019_bib79","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0022-5347(05)00736-6","article-title":"Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer","volume":"175","author":"Xia","year":"2006","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.vetimm.2025.111019_bib80","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.eururo.2009.09.013","article-title":"Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles","volume":"57","author":"Birkhahn","year":"2010","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.vetimm.2025.111019_bib81","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1186\/s12885-018-4409-3","article-title":"Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq","volume":"18","author":"Maeda","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.vetimm.2025.111019_bib82","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.4049\/jimmunol.181.2.1460","article-title":"Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to shiga toxin","volume":"181","author":"Zanchi","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.vetimm.2025.111019_bib83","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/labinvest.2012.156","article-title":"ERK pathway and sheddases play an essential role in ethanol-induced CX3CL1 release in pancreatic stellate cells","volume":"93","author":"Uchida","year":"2013","journal-title":"Lab Invest."},{"issue":"10","key":"10.1016\/j.vetimm.2025.111019_bib84","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s11626-022-00736-0","article-title":"Establishment and characterization of urothelial carcinoma cell lines with and without BRAF mutation (V595E) in dogs","volume":"58","author":"Yamasaki","year":"2022","journal-title":"Vitr. Cell Dev. Biol. Anim."},{"issue":"11","key":"10.1016\/j.vetimm.2025.111019_bib85","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.3748\/wjg.v20.i11.2979","article-title":"Differential gene expression of chemokines in KRAS and BRAF mutated colorectal cell lines: role of cytokines","volume":"20","author":"Khan","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"17","key":"10.1016\/j.vetimm.2025.111019_bib86","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1158\/0008-5472.CAN-18-0365","article-title":"Oncogenic BRAF V600E governs regulatory T cell recruitment during melanoma tumorigenesis","volume":"78","author":"Shabaneh","year":"2018","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.vetimm.2025.111019_bib87","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/0300985820967449","article-title":"BRAFV595E mutation associates CCL17 expression and regulatory T cell recruitment in urothelial carcinoma of dogs","volume":"58","author":"Maeda","year":"2021","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.vetimm.2025.111019_bib88","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5535578","article-title":"IL-6 promotes the proliferation and immunosuppressive function of myeloid-derived suppressor cells via the MAPK signaling pathway in bladder cancer","volume":"2021","author":"Zheng","year":"2021","journal-title":"Biomed. Res Int"},{"issue":"1","key":"10.1016\/j.vetimm.2025.111019_bib89","doi-asserted-by":"crossref","first-page":"5.e17","DOI":"10.1016\/j.urolonc.2018.06.009","article-title":"Granulocytic myeloid-derived suppressor cells correlate with outcomes undergoing neoadjuvant chemotherapy for bladder cancer","volume":"38","author":"Yang","year":"2020","journal-title":"Urol. Oncol."},{"issue":"9","key":"10.1016\/j.vetimm.2025.111019_bib90","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.urolonc.2018.02.018","article-title":"Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy","volume":"36","author":"Ornstein","year":"2018","journal-title":"Urol. Oncol."},{"issue":"3","key":"10.1016\/j.vetimm.2025.111019_bib91","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10557-015-6589-2","article-title":"Aspirin action in endothelial cells: different patterns of response between chemokine CX3CL1\/CX3CR1 and TNF-\u03b1\/TNFR1 signaling pathways","volume":"29","author":"Szukiewicz","year":"2015","journal-title":"Cardiovasc Drugs Ther."}],"container-title":["Veterinary Immunology and Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242725001394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242725001394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:16:26Z","timestamp":1773807386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165242725001394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":91,"alternative-id":["S0165242725001394"],"URL":"https:\/\/doi.org\/10.1016\/j.vetimm.2025.111019","relation":{},"ISSN":["0165-2427"],"issn-type":[{"value":"0165-2427","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sorafenib inhibits myeloid-derived suppressor cell infiltration in canine transitional cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Veterinary Immunology and Immunopathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vetimm.2025.111019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111019"}}